Allan Marchington has been a partner at Apposite Capital since its inception in 2006. Previously, Allan was worked Abingworth Management, Millennium Pharmaceuticals, Cambridge Combinatorial and Pfizer. He has a PhD in Synthetic Chemistry from the University of Liverpool.
Dr Dix is also Non-Executive Chairman of Modern Biosciences plc. He has more than 20 years’ experience in life science research, with over 15 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology. Dr Dix’s expertise includes an in depth understanding of all facets of drug discovery and development, a broad knowledge of the science and commercial landscape of a variety of therapeutic areas, and solid experience of the pharmaceutical business and finance community supporting the sector.
Mr Edwards has been Chief Executive Officer of Antisoma plc since March 1998. Prior to joining Antisoma he was Director of Business Development at Therapeutic Antibodies. Aisling Burnand, Chief Executive of the BIA, said: “I would like to welcome our new Board Directors and thank those Board Directors who are standing down at the end of the year. The collective experience of our Board is extremely valuable to the BIA and their sector experience is integral to determining our strategy going forward.”
For further information, please contact Robert Winder, Communications Executive, 020 7565 7193; mobile 07825 942 934.
BioIndustry Association Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades. With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society. For further information, please go to: www.bioindustry.org
